Andrea Eleazar, MHS

“We believe that the combination of [Tafa-Len-R-CHOP] is a potential new standard for frontline therapy for patients with intermediate or high-risk [DLBCL] or [HGBL],” said Georg Lenz, MD.

SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed myeloma.

Long-term RUBY data show dostarlimab plus chemo drives durable remission and potential cure in many patients with dMMR/MSI-H advanced or recurrent endometrial cancer.

FDA grants orphan drug status to EO2463 vaccine for watch-and-wait indolent NHL, advancing a potential treatment option and spotlighting promising SIDNEY trial data.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.

FDA fast tracks STX-0712, a CCR2-targeted CyTAC, as phase 1 trial enrolls to tackle relapsed/refractory CMML and monocytic AML.

New survey reveals CLL physicians and patients vary widely on post-BTK inhibitor tradeoffs, urging shared decisions beyond survival data.

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

Older men with CLL on BTK inhibitors face sharply higher atrial fibrillation risk, shaping drug choice and prompting stronger cardiovascular screening and monitoring.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

FDA grants orphan status to CLN‑049, an FLT3xCD3 T‑cell engager in phase 1, for relapsed/refractory patients with AML.

Rural patients with cancer face crushing costs, travel hurdles, and medical debt; new ACS CAN data show care delays and highlights patient navigation as relief.

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and patients face next.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

Final PRIMO phase 2 data show oral duvelisib drives strong responses in relapsed PTCL, standout AITL benefit, with manageable safety signals.

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

Phase 3 FLASH2 ends early after interim analysis shows synthetic hypericin photodynamic therapy fails to improve CTCL outcomes, prompting deeper data review and regulator talks.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

Study finds Gemini and GPT catch oncology chart errors, improving documentation accuracy and patient safety with clinician oversight.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

Odronextamab delivers higher responses and longer control in later-line follicular lymphoma versus real-world therapies, new analysis reports.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

Nearly 60% of under-50 cancers are screen-detectable; Ohio State’s BRIDGE program coordinates care, research, and support for younger adults.

Why oncology telehealth stalls: patients cite platform anxiety, few video offers, and in-person trust—pointing to hybrid care.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.